Compare McKesson Corporation (MCK) vs Nokia Corp (NOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Nokia Corp — how do they compare? McKesson Corporation trades at $832.45 (market cap $97.35B), while Nokia Corp trades at $11.02 (market cap $56.70B). The key difference: McKesson Corporation is the larger of the two by market cap, and Nokia Corp pays the higher dividend (1.63%). Which is the better fit depends on your goals.
| MCK | NOK | |
|---|---|---|
Market Cap | $97.35B | $56.70B |
Sector | Health | Technology |
52-Week High | $995.69 | $16.83 |
52-Week Low | $659.01 | $4.05 |
Enterprise Value | $101.98B | $53.51B |
Dividend Yield | 0.39% | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $828.84, down 1.49% on the day, with a bullish technical outlook supported by moving averages and key support at $826. The company shows strong revenue growth, reaching $359.05B in 2025, and has beaten EPS estimates for three consecutive quarters. Analyst sentiment is overwhelmingly positive with 24 buy ratings and a consensus price target of $932.83, indicating 12.5% upside potential.
The outlook for MCK remains favorable due to consistent earnings beats, robust cash flow generation, and leadership in healthcare distribution. Risks include thin profit margins (1.18% net margin) and high liabilities relative to equity. Investors should focus on execution in specialty pharma and oncology services as key growth drivers amid competitive and regulatory pressures.
Nokia (NOK) trades at $10.65, up 5.24% on the day, with a bullish analyst consensus price target of $18.00 representing significant upside. Recent earnings show mixed results with a Q1 2026 miss but Q3 and Q4 2025 beats. The company is pivoting toward AI and 5G infrastructure, evidenced by new partnerships and strong revenue growth in these segments. Technical indicators are mixed, with oscillators bullish but moving averages bearish, suggesting near-term consolidation.
The outlook is cautiously optimistic, driven by AI networking demand and strategic deals, but risks include intense competition and execution challenges. Valuation appears stretched with a P/E of 63.22, requiring sustained earnings growth to justify current levels. The stock offers potential for long-term growth if AI initiatives deliver, but near-term volatility is likely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
